Enalapril Maleate Tablets

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DLA TROOP SUPPORT

Contract Value

Not provided

Codes & Classification
Solicitation Number

SPE2D2-25-D-0008

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

Haifa Bay, Haifa, ISRAEL

SourceSAM
Documents3
The Defense Logistics Agency (DLA) Troop Support, operating under the Department of Defense, has issued an award notice for the procurement of Enalapril Maleate Tablets, as detailed under procurement identifier SPE2D2-25-D-0008. This contract pertains to the manufacturing and supply of pharmaceutical preparations, specifically Enalapril Maleate Tablets, which are widely used in the treatment of hypertension and certain cardiac conditions. The contract falls under NAICS code 325412 (Pharmaceutical Preparation Manufacturing) and Product Service Code 6505, indicating its focus on medical and pharmaceutical products. The notice announces the exercise of Option Year 1 for the contract, extending its effective period from March 4, 2026, through March 3, 2027. This extension ensures the continued supply of Enalapril Maleate Tablets to meet the ongoing requirements of the Department of Defense. Additionally, the contract has been modified in accordance with DoD Class Deviation 2025-O0003, reflecting compliance with updated regulatory or policy directives relevant to this procurement. The place of performance for this contract is specified as Haifa Bay, Haifa, Israel (IL-HA), indicating that the manufacturing or supply operations will be conducted from this location. This international aspect may require contractors to demonstrate robust capabilities in global pharmaceutical manufacturing and logistics, as well as adherence to applicable U.S. and international regulations. DLA Troop Support serves as the contracting entity, with oversight and administration provided by its federal office. The primary points of contact for this procurement are Kyle Lewicki ([email protected], 445-737-0977) and Jason Wray ([email protected], 445-737-6304), who can provide further information regarding contract specifics and compliance requirements. This award notice is active as of February 24, 2026, and is published on SAM.gov, where additional attachments related to the opportunity are available for review. Contractors interested in this opportunity should note the long-term nature of the contract, the requirement for consistent pharmaceutical quality, and the necessity to comply with all Department of Defense and DLA Troop Support standards throughout the contract lifecycle. Overall, this procurement activity is designed to ensure a reliable supply of Enalapril Maleate Tablets for defense-related healthcare needs, with a focus on quality, regulatory compliance, and timely delivery from an international manufacturing base.